Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,291 Shares

by · The Cerbat Gem

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) CEO Berndt Modig sold 2,291 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $31.07, for a total value of $71,181.37. Following the completion of the sale, the chief executive officer owned 135,209 shares in the company, valued at $4,200,943.63. The trade was a 1.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Berndt Modig also recently made the following trade(s):

  • On Monday, May 18th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $29.22, for a total value of $66,972.24.
  • On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The stock was sold at an average price of $28.60, for a total value of $65,551.20.
  • On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The stock was sold at an average price of $27.74, for a total value of $647,257.42.

Pharvaris Price Performance

NASDAQ PHVS traded up $1.95 during trading hours on Wednesday, reaching $33.41. The company’s stock had a trading volume of 287,421 shares, compared to its average volume of 243,226. The firm has a market capitalization of $2.19 billion, a price-to-earnings ratio of -10.51 and a beta of -2.35. Pharvaris N.V. has a 1-year low of $16.00 and a 1-year high of $33.50. The company’s 50-day moving average is $29.71 and its two-hundred day moving average is $27.63.

Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Equities analysts forecast that Pharvaris N.V. will post -3.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new stake in Pharvaris during the 4th quarter worth about $35,000. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Pharvaris in the 3rd quarter valued at about $75,000. Barclays PLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Pharvaris in the 4th quarter valued at about $86,000.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a report on Tuesday. Wolfe Research started coverage on Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price target for the company. Wedbush increased their price target on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Finally, Royal Bank Of Canada lowered their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a report on Monday, April 6th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

Get Our Latest Research Report on Pharvaris

Pharvaris Company Profile

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Recommended Stories